Literature DB >> 26961577

Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates.

Lee Aymar Ndounga Diakou1, Ludovic Trinquart, Asbjørn Hróbjartsson, Caroline Barnes, Amelie Yavchitz, Philippe Ravaud, Isabelle Boutron.   

Abstract

BACKGROUND: Assessment of events by adjudication committees (ACs) is recommended in multicentre randomised controlled trials (RCTs). However, its usefulness has been questioned.
OBJECTIVES: The aim of this systematic review was to compare 1) treatment effect estimates of subjective clinical events assessed by onsite assessors versus by AC, and 2) treatment effect estimates according to the blinding status of the onsite assessor as well as the process used to select events to adjudicate. SEARCH
METHODS: We searched Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, PsycINFO, CINAHL and Google Scholar (25 August 2015 as the last updated search date), using a combination of terms to retrieve RCTs with commonly used terms to describe ACs. SELECTION CRITERIA: We included all reports of RCTs and the published RCTs included in reviews and meta-analyses that reported the same subjective outcome event assessed by both an onsite assessor and an AC. DATA COLLECTION AND ANALYSIS: We extracted the odds ratio (OR) from onsite assessment and the corresponding OR from AC assessment and calculated the ratio of the odds ratios (ROR). A ratio of odds ratios < 1 indicated that onsite assessors generated larger effect estimates in favour of the experimental treatment than ACs. MAIN
RESULTS: Data from 47 RCTs (275,078 patients) were used in the meta-analysis. We excluded 11 RCTs because of incomplete outcome data to calculate the OR for onsite and AC assessments. On average, there was no difference in treatment effect estimates from onsite assessors and AC (combined ROR: 1.00, 95% confidence interval (CI) 0.97 to 1.04; I(2) = 0%, 47 RCTs). The combined ROR was 1.00 (95% CI 0.96 to 1.04; I(2) = 0%, 35 RCTs) when onsite assessors were blinded; 0.76 (95% CI 0.48 to 1.12, I(2) = 0%, two RCTs) when AC assessed events identified independently from unblinded onsite assessors; and 1.11 (95% CI 0.96 to 1.27, I(2) = 0%, 10 RCTs) when AC assessed events identified by unblinded onsite assessors. However, there was a statistically significant interaction between these subgroups (P = 0.03) AUTHORS'
CONCLUSIONS: On average, treatment effect estimates for subjective outcome events assessed by onsite assessors did not differ from those assessed by ACs. Results of subgroup analysis showed an interaction according to the blinded status of onsite assessors and the process used to submit data to AC. These results suggest that the use of ACs might be most important when onsite assessors are not blinded and the risk of misclassification is high. Furthermore, research is needed to explore the impact of the different procedures used to select events to adjudicate.

Entities:  

Mesh:

Year:  2016        PMID: 26961577      PMCID: PMC7187204          DOI: 10.1002/14651858.MR000043.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  84 in total

1.  Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy.

Authors:  Christopher M O'Connor; Steven Gottlieb; Jamieson M Bourque; Heidi Krause-Steinrauf; Inder Anand; Jeffrey L Anderson; Jonathan F Plehn; Marc A Silver; Michel White; Peter Carson
Journal:  Am J Cardiol       Date:  2005-03-01       Impact factor: 2.778

2.  Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).

Authors:  S H L Thomas; M D Drici; G C Hall; M A Crocq; B Everitt; M H Lader; C Le Jeunne; D Naber; S Priori; M Sturkenboom; F Thibaut; J Peuskens; A Mittoux; P Tanghøj; M Toumi; N D Moore; R D Mann
Journal:  Acta Psychiatr Scand       Date:  2010-11       Impact factor: 6.392

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  Oral rivaroxaban for symptomatic venous thromboembolism.

Authors:  Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong
Journal:  N Engl J Med       Date:  2010-12-03       Impact factor: 91.245

5.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

6.  Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.

Authors:  Kenneth W Mahaffey; June L Wampole; Amanda Stebbins; Lisa G Berdan; Donna McAfee; Tyrus L Rorick; John K French; Neal S Kleiman; Christopher M O'Connor; Eric A Cohen; Christopher B Granger; Paul W Armstrong
Journal:  Contemp Clin Trials       Date:  2011-01-08       Impact factor: 2.226

7.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

8.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

Review 9.  Adjudication-related processes are underreported and lack standardization in clinical trials of venous thromboembolism: a systematic review.

Authors:  Anna K Stuck; Evelyn Fuhrer; Andreas Limacher; Marie Méan; Drahomir Aujesky
Journal:  J Clin Epidemiol       Date:  2013-11-28       Impact factor: 6.437

10.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.

Authors:  Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne
Journal:  BMJ       Date:  2011-10-18
View more
  17 in total

1.  Japan-Retinal Detachment Registry Report I: preoperative findings in eyes with primary retinal detachment.

Authors:  Taiji Sakamoto; Sumihiro Kawano; Ryo Kawasaki; Akito Hirakata; Hidetoshi Yamashita; Shuichi Yamamoto; Tatsuro Ishibashi
Journal:  Jpn J Ophthalmol       Date:  2019-11-23       Impact factor: 2.447

Review 2.  Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates.

Authors:  Lee Aymar Ndounga Diakou; Ludovic Trinquart; Asbjørn Hróbjartsson; Caroline Barnes; Amelie Yavchitz; Philippe Ravaud; Isabelle Boutron
Journal:  Cochrane Database Syst Rev       Date:  2016-03-10

3.  Use of Medicare Claims to Identify Adverse Clinical Outcomes After Mitral Valve Repair.

Authors:  Angela Lowenstern; Steven J Lippmann; J Matthew Brennan; Tracy Y Wang; Lesley H Curtis; Ted Feldman; Donald D Glower; Bradley G Hammill; Sreekanth Vemulapalli
Journal:  Circ Cardiovasc Interv       Date:  2019-05       Impact factor: 6.546

4.  Outcome assessment by central adjudicators in randomised stroke trials: Simulation of differential and non-differential misclassification.

Authors:  Peter J Godolphin; Philip M Bath; Christopher Partlett; Eivind Berge; Martin M Brown; Misha Eliasziw; Per Morten Sandset; Joaquín Serena; Alan A Montgomery
Journal:  Eur Stroke J       Date:  2020-02-26

5.  Central adjudication of serious adverse events did not affect trial's safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial.

Authors:  Peter J Godolphin; Alan A Montgomery; Lisa J Woodhouse; Daniel Bereczki; Eivind Berge; Rónán Collins; Exuperio Díez-Tejedor; John Gommans; Kennedy R Lees; Serefnur Ozturk; Stephen Phillips; Stuart Pocock; Kameshwar Prasad; Szabolcs Szatmari; Yongjun Wang; Philip M Bath; Nikola Sprigg
Journal:  PLoS One       Date:  2018-11-26       Impact factor: 3.240

Review 6.  Central masked adjudication of stroke diagnosis at trial entry offered no advantage over diagnosis by local clinicians: Secondary analysis and simulation.

Authors:  Peter J Godolphin; Trish Hepburn; Nikola Sprigg; Liz Walker; Eivind Berge; Ronan Collins; John Gommans; George Ntaios; Stuart Pocock; Kameshwar Prasad; Joanna M Wardlaw; Philip M Bath; Alan A Montgomery
Journal:  Contemp Clin Trials Commun       Date:  2018-11-10

7.  Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Colin Baigent; William G Herrington; Josef Coresh; Martin J Landray; Adeera Levin; Vlado Perkovic; Marc A Pfeffer; Peter Rossing; Michael Walsh; Christoph Wanner; David C Wheeler; Wolfgang C Winkelmayer; John J V McMurray
Journal:  Kidney Int       Date:  2017-08       Impact factor: 10.612

Review 8.  Kidney disease trials for the 21st century: innovations in design and conduct.

Authors:  William G Herrington; Natalie Staplin; Richard Haynes
Journal:  Nat Rev Nephrol       Date:  2019-10-31       Impact factor: 28.314

9.  Investigating the effect of independent, blinded digital image assessment on the STOP GAP trial.

Authors:  Emily Patsko; Peter J Godolphin; Kim S Thomas; Trish Hepburn; Eleanor J Mitchell; Fiona E Craig; Philip M Bath; Alan A Montgomery
Journal:  Trials       Date:  2017-02-02       Impact factor: 2.279

10.  Outcome measures in clinical trials of treatments for acute severe haemorrhage.

Authors:  Amy Brenner; Monica Arribas; Jack Cuzick; Vipul Jairath; Simon Stanworth; Katharine Ker; Haleema Shakur-Still; Ian Roberts
Journal:  Trials       Date:  2018-10-01       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.